EPO

Erythropoietin

Hormones

What is Erythropoietin?

Erythropoietin (EPO) is a glycoprotein hormone produced primarily by peritubular interstitial fibroblasts in the renal cortex (approximately 90%), with a smaller contribution from the liver (approximately 10%). EPO is the principal regulator of erythropoiesis—the production of red blood cells in the bone marrow. Its secretion is driven by tissue oxygen sensing: when the kidneys detect hypoxia (low oxygen), hypoxia-inducible factor (HIF) proteins accumulate and activate EPO gene transcription, increasing EPO production and stimulating red blood cell production to improve oxygen delivery.

EPO acts on erythroid progenitor cells in the bone marrow by binding to EPO receptors, promoting their survival, proliferation, and differentiation into mature red blood cells. Under normal conditions, EPO maintains a steady-state rate of erythropoiesis. In response to acute blood loss, hemolysis, or altitude exposure, EPO levels can increase 100–1000-fold. Recombinant EPO (epoetin alfa, darbepoetin) is used therapeutically to treat anemia of chronic kidney disease and chemotherapy-induced anemia, and has been infamously misused as a performance-enhancing drug in endurance athletics.

Why It Matters

EPO measurement is essential for evaluating unexplained polycythemia (elevated red blood cells/hemoglobin). The EPO level distinguishes primary polycythemia vera (a myeloproliferative neoplasm where bone marrow autonomously overproduces red blood cells, suppressing EPO) from secondary polycythemia (where EPO is appropriately elevated in response to hypoxia, or inappropriately elevated by an EPO-secreting tumor). EPO is also important in evaluating anemia in chronic kidney disease—as kidney function declines, EPO production falls, leading to progressive anemia that can be treated with recombinant EPO.

Normal Reference Ranges

GroupRangeUnit
Adults4–24mIU/mL

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High EPO Levels Mean

Common Causes

  • Secondary polycythemia (chronic hypoxia: COPD, sleep apnea, high altitude)
  • EPO-secreting tumors (renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma)
  • Anemia (appropriately elevated as a compensatory response)
  • Post-hemorrhage (acute blood loss)
  • Exogenous EPO administration (doping or therapeutic)
  • Cyanotic congenital heart disease

Possible Symptoms

  • Elevated hemoglobin and hematocrit (polycythemia)
  • Ruddy or plethoric complexion
  • Headaches and dizziness
  • Hypertension
  • Increased blood viscosity and thrombosis risk
  • Often the symptoms reflect the underlying cause (dyspnea from lung disease, etc.)

What to do: Elevated EPO with elevated hemoglobin suggests secondary polycythemia. Evaluate for chronic hypoxia with pulse oximetry, arterial blood gas, and sleep study (obstructive sleep apnea is a common cause). CT or MRI of the kidneys, liver, and brain may be needed to rule out EPO-secreting tumors. If secondary causes are identified, treatment targets the underlying condition (CPAP for sleep apnea, supplemental oxygen for lung disease). Phlebotomy may be needed to reduce blood viscosity if hematocrit is dangerously elevated (>55%). If hemoglobin is normal or low with high EPO, the marrow is either responding appropriately to anemia or unable to respond (iron deficiency, myelodysplasia).

What Low EPO Levels Mean

Common Causes

  • Polycythemia vera (autonomous marrow production suppresses EPO)
  • Chronic kidney disease (impaired EPO production)
  • End-stage renal disease
  • Chronic inflammation (inflammatory cytokines suppress EPO)
  • Autonomic neuropathy affecting renal oxygen sensing

Possible Symptoms

  • Anemia (in CKD): fatigue, pallor, shortness of breath, exercise intolerance
  • Polycythemia symptoms (in PV): headache, pruritus, plethora, splenomegaly
  • The clinical picture depends on whether low EPO is causing anemia or is secondary to polycythemia

What to do: Low EPO with polycythemia strongly suggests polycythemia vera—confirm with JAK2 V617F mutation testing (positive in >95% of PV cases) and complete blood count with differential. Treatment of PV includes phlebotomy to maintain hematocrit <45%, low-dose aspirin, and cytoreductive therapy (hydroxyurea) for high-risk patients. Low EPO with anemia indicates renal insufficiency or chronic disease as the anemia etiology. In CKD-related anemia, recombinant EPO or erythropoiesis-stimulating agents (ESAs) are the cornerstone treatment, targeting hemoglobin of 10–11.5 g/dL (not full correction, as higher targets increase cardiovascular risk). Iron stores must be repleted before or during ESA therapy.

When Is EPO Testing Recommended?

  • When distinguishing polycythemia vera from secondary polycythemia
  • When evaluating anemia in chronic kidney disease
  • When investigating unexplained polycythemia
  • When an EPO-secreting tumor is suspected

Frequently Asked Questions

Recombinant EPO has been misused by endurance athletes since the early 1990s because it increases red blood cell production, hemoglobin levels, and oxygen-carrying capacity—directly improving aerobic performance. EPO abuse was central to some of the biggest doping scandals in professional cycling and other endurance sports. The performance gains are significant: EPO can increase VO2 max by 5–10%. However, EPO doping is dangerous—excessive red blood cell production increases blood viscosity, raising the risk of stroke, heart attack, pulmonary embolism, and sudden death, particularly during sleep or dehydration. Anti-doping authorities use direct detection of recombinant EPO (which differs slightly from endogenous EPO) and indirect methods (Athlete Biological Passport monitoring hemoglobin and reticulocyte parameters over time).
The kidneys are the primary source of EPO production (approximately 90%). As kidney function declines in CKD, the peritubular fibroblasts that produce EPO are damaged and replaced by fibrotic tissue, resulting in inadequate EPO production relative to the degree of anemia—this is called "relative EPO deficiency." The anemia of CKD typically becomes clinically significant when GFR falls below 30–40 mL/min (stage 3b–4 CKD). It is a normocytic, normochromic anemia with an inappropriately low reticulocyte count. Additional factors contributing to CKD anemia include iron deficiency (from reduced absorption, chronic blood loss during dialysis), inflammation (hepcidin elevation reducing iron availability), reduced red cell survival, and uremic toxins suppressing erythropoiesis.
The 2019 Nobel Prize in Physiology or Medicine was awarded to William Kaelin Jr., Peter Ratcliffe, and Gregg Semenza for their discovery of how cells sense and adapt to oxygen availability—work that began with studying EPO gene regulation. They discovered the hypoxia-inducible factor (HIF) pathway: under normal oxygen conditions, HIF proteins are continuously produced but rapidly degraded via the VHL-mediated ubiquitin-proteasome pathway. Under hypoxia, HIF accumulates and activates genes involved in the adaptive response, including EPO. This discovery has led to a new class of medications called HIF-prolyl hydroxylase inhibitors (HIF-PHIs, e.g., roxadustat, daprodustat) that stabilize HIF to stimulate endogenous EPO production—offering an oral alternative to injectable EPO for CKD anemia.

Related Biomarkers

HgbHemoglobinHctHematocritRBCRed Blood CellsFeSerum IronFerritinFerritin

Want your EPO levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.

Disclaimer: SymptomGPT is not a medical diagnosis tool and does not provide medical advice. Always consult a qualified healthcare professional. If you are experiencing a medical emergency, call 911 immediately.